Insilico Medicine and Bora Pharmaceuticals announce AI-driven drug discovery partnership
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd., a…
Read the full articleYou might also wanna read
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore
StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III
Insilico Medicine, an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants,
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 13, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generativ
Takeda signs $600M AI drug discovery deal with Insilico
Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japan
Insilico + CMS $1.2B CNS AI Drug Deal Explained (July 2026)
Insilico Medicine and China Medical System expanded their AI drug discovery collaboration July 12, 2026 with ~1.2B RMB milestones. What it i
Insilico Medicine advances AI drug for IPF to Phase III trials
Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF).
Comments
Sign in to join the conversation.
No comments yet. Be the first.